In the last trading session, 1.14 million shares of the IGC Pharma Inc (AMEX:IGC) were traded, and its beta was 1.49. Most recently the company’s share price was $0.37, and it changed around $0.0 or -0.65% from the last close, which brings the market valuation of the company to $30.72M. IGC currently trades at a discount to its 52-week high of $0.48, offering almost -29.73% off that amount. The share price’s 52-week low was $0.25, which indicates that the current value has risen by an impressive 32.43% since then. We note from IGC Pharma Inc’s average daily trading volume that its 10-day average is 1.8 million shares, with the 3-month average coming to 2.56 million.
IGC Pharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended IGC as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. IGC Pharma Inc is expected to report earnings per share of -0.03 for the current quarter.
IGC Pharma Inc (AMEX:IGC) trade information
Instantly IGC has showed a red trend with a performance of -0.65% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.4100 on recent trading dayincreased the stock’s daily price by 9.76%. The company’s shares are currently down -22.81% year-to-date, but still up 2.01% over the last five days. On the other hand, IGC Pharma Inc (AMEX:IGC) is 19.09% up in the 30-day period. We can see from the shorts that 3.46 million shares have been sold at a short interest cover period of 0.5 day(s).
IGC Pharma Inc (IGC) estimates and forecasts
The year-over-year growth rate is expected to be 14.12%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 326k in revenue for the current quarter. 1 analysts expect IGC Pharma Inc to make 494k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 272k and 412k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 19.85%. Forecasts for the next quarter put sales growth at 19.90%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 12.85%.
IGC Dividends
IGC Pharma Inc’s next quarterly earnings report is expected to be released on 2025-Jun-27.
IGC Pharma Inc (AMEX:IGC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.16% of IGC Pharma Inc shares, and 19.89% of them are in the hands of institutional investors. The stock currently has a share float of 21.89%. IGC Pharma Inc stock is held by 26.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 1.1961% of the shares, which is about 0.7 million shares worth $0.31 million.
VANGUARD GROUP INC, with 1.0965% or 0.65 million shares worth $0.28 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 630.22 shares worth $0.23 million, making up 1.59% of all outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held roughly 392.97 shares worth around $0.14 million, which represents about 0.99% of the total shares outstanding.
